Iricryn (Bimatoprost)

Bimatoprost activates prostaglandin F (FP) receptors in the eye, increasing the uveoscleral outflow of aqueous humor. This enhanced drainage reduces intra‑ocular pressure, which is the primary therapeutic goal in glaucoma and ocular hypertension.

The dosing regimen for Iricryn is determined by the prescribing ophthalmologist. Typically, one drop is instilled into the affected eye(s) once daily in the evening, but the exact dose and frequency are individualized.

Iricryn is classified as Pregnancy Category C. It should only be used if the potential benefit justifies the potential risk to the fetus. Breastfeeding mothers should consult their healthcare provider, as the drug may be present in milk.

To order Iricryn, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and necessary import documentation.

Iricryn (bimatoprost) belongs to the prostaglandin analog class, which generally offers potent intra‑ocular pressure reduction with once‑daily dosing. Compared with beta‑blocker drops, prostaglandin analogs often have a stronger pressure‑lowering effect and a different side‑effect profile, such as increased eyelash growth.

Store Iricryn at room temperature, below 25 °C. Keep the bottle tightly closed, protect it from light and moisture, and do not freeze. Follow any additional storage instructions on the product label.

Iricryn is applied as an eye drop. The patient should wash hands, tilt the head back, pull down the lower eyelid to form a pocket, and place one drop into the conjunctival sac. Close the eye gently and avoid blinking excessively for a few minutes.

Serious risks include anterior uveitis, cystoid macular edema, severe allergic reactions, and sudden loss of vision. Patients should report any eye pain, redness, vision changes, or swelling promptly to their eye care professional.

Iricryn should not be used by individuals with active ocular infection or inflammation, known hypersensitivity to bimatoprost or any component of the formulation, or by patients with corneal endothelial dysfunction without close monitoring.